Good MorningEquity markets fell hard on Monday to not only confirm resistance at the S&P 500 level of 4,300 but to break through potential support at the 4,150 level as well. The move also confirms a much larger Head & Shoulders pattern that has been in play all year. This pattern has not only a long-term but a deep implication that could lead the S&P 500 down to the 2,700 level and keep it trending at low levels for an extended period of time. The major culprit for the move is slowing economic activity and the possibility of a deepening recession.
This week, the biggest risk for the market will come on Friday with the release of the PCE Price Index. The index is expected to show a slowdown in the monthly advance of consumer level inflation but for core consumer inflation to remain at record levels on a YOY basis. A better-than-expected figure could send the market higher but a worse-than-expected number will most defiantly send it lower on an increased expectation for another aggressive FOMC interest rate increase. Featured: How This Market Leads To The Biggest Bull Market Ever (Darwin) 
|
Stocks | | | Oil-and-gas explorer and producer Denbury (NYSE: DEN) has been in rally mode since mid-July and is working on its second month in a row of double-digit price gains. Both earnings and rumors of a sale are driving the increases.
The stock bolted 19.87% higher in July, and has tacked on another 28.56%... Read the Full Story |
|
From Our PartnersThere's still plenty of upside ahead for gold stocks.
Goldman Sachs says gold could run to $2,500 by the end of the year-especially with fears of a potential recession. And, according to Jeff Currie, Goldman Sachs global head of commodities research, as quoted by Bloomberg, "It's a perfect storm for gold right now."
So, where should we invest? Try these. | | Click Here to Download the FREE Report |
|
Markets | | |
Industrial stocks are ideal to buy in a bull market. Companies tend to increase spending when their cost of capital is cheap. But with rising interest rates, an uncertain employment picture, and geopolitical concerns industrial stocks look less compelling.
And as an overall sector, th... Read the Full Story |
|
Stocks | | | Global demand for copper is soaring, but does that put suppliers like Freeport-McMoRan (NYSE:FCX), Teck Resources (NYSE: TECK) and Southern Copper (NYSE: SCCO) in a position to rally?
Copper is a crucial component in several areas poised for growth: Electric vehicles, wind and solar power, an... Read the Full Story |
|
From Our PartnersIncome expert Marc Lichtenfeld is giving away his Ultimate Dividend Package. Inside, you'll get the names and ticker symbols of his TOP FIVE dividend stocks right now, including an "A"-rated, ultra-safe dividend stock with a huge 8% yield and his No. 1 dividend stock for a LIFETIME of income. | | Click here before the download link expires. |
|
Markets | | |
Besides the shared nomenclature, Beyond Meat, Inc. (NASDAQ: BYND) may have more in common with Bed Bath & Beyond than “meats” the eye.
Last week shares of the specialty retailer soared as high as $30 despite an absence of news. Traders bought more than $130 million worth of the po... Read the Full Story |
|
Markets | | |
Insurance fintech platform provider Lemonade (NYSE: LMND) stock has surged off its $15.99 lows in May to double after its earnings release in August 2022. The insurtech disruptor is trying to break the conventional mold in the five trillion dollar insurance industry. It’s artificial intellig... Read the Full Story |
|
|
Markets | | | Stocks fell broadly in afternoon trading on Wall Street Monday, extending the market’s losses amid worries about inflation and the path ahead for the economy.
The S&P 500 fell 2.1% as of 3:07 p.m. Eastern and more than 90% of stocks in the benchmark index posted losses. It finishe... Read the Full Story |
|
Politics | | | Warren Buffett’s company now has clearance to boost its current 20% stake in Occidental Petroleum up to 50% of the oil producer, but it’s not immediately clear how many more shares Berkshire Hathaway plans to buy Read the Full Story |
|
Politics | | | A company seeking to mine in Georgia near the edge of the Okefenokee Swamp's vast wildlife refuge said Monday that its project is back on track after a federal agency reversed a June decision that had posed a big setback.
Twin Pines Minerals said the Army Corps of Engineers has agreed... Read the Full Story |
|
Politics | | | Russia's invasion of Ukraine has already killed some 9,000 Ukrainian soldiers since it began nearly six months ago, a general said, and the fighting Monday showed no signs that the war is abating.
At a veteran's event, Ukraine’s military chief, Gen. Valerii Zaluzhnyi, said many of Ukr... Read the Full Story |
|
Politics | | | German leader Olaf Scholz says he's working as fast as he can to reduce Germany's dependence on Russia for energy, but Canadian Prime Minister Justin Trudeau says a business case is needed to send gas from Canada to Europe Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. | | View Today's Stock Pick |
|
